Italian pediatric and adult oncology communities join forces for a national project dedicated to adolescents and young adults with cancer

2021 ◽  
pp. 030089162110587
Author(s):  
Andrea Ferrari ◽  
Paola Quarello ◽  
Maurizio Mascarin ◽  
Giuseppe Luigi Banna ◽  
Angela Toss ◽  
...  

Adolescents and young adults with cancer have substantially different clinical and psychological needs compared to those of pediatric patients and of older adult patients. We describe the development of an Italian national project dedicated to adolescents and young adults with cancer.

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Yi Feng Wen ◽  
Meng Xuan Chen ◽  
Guosheng Yin ◽  
Ruitao Lin ◽  
Yu Jie Zhong ◽  
...  

Abstract Background Accurate appraisal of burden of adolescents and young adults (AYAs) cancers is crucial to informing resource allocation and policy making. We report on the latest estimates of burden of AYA cancers in 204 countries and territories between 1990 and 2019 in association with socio-demographic index (SDI). Patients and methods Estimates from the Global Burden of Disease study 2019 were used to analyse incidence, mortality, and disability-adjusted life years (DALYs) due to AYA cancers at global, regional, and national levels by sex. Association between AYA cancer burden and SDI were investigated. Burdens of AYA cancers were contextualized in comparison with childhood and older adult cancers. All estimates are reported as counts and age-standardized rates per 100,000 person-years. Results In 2019, there were 1.2 million incident cases, 0.4 million deaths, and 23.5 million DALYs due to AYA cancers globally. The highest age-standardized incidence rate occurred in Western Europe (75.3 [Females] and 67.4 [Males] per 100,000 person-years). Age-standardized death (23.2 [Females] and 13.9 [Males] per 100,000 person-years) and DALY (1328.3 [Females] and 1059.2 [Males] per 100,000 person-years) rates were highest in Oceania. Increasing SDI was associated with a higher age-standardized incidence rate. An inverted U-shaped association was identified between SDI and death and DALY rates. AYA cancers collectively is the second leading cause of non-communicable diseases-related deaths globally in 2019. DALYs of AYA cancers ranked the second globally and the first in low and low-middle SDI locations when compared with that of childhood and older adult cancers. Conclusion The global burden of AYA cancers is substantial and disproportionally affect populations in limited-resource settings. Capacity building for AYA cancers is essential in promoting equity and population health worldwide.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 2387-2387
Author(s):  
Erina Quinn ◽  
Charlotte Yuan ◽  
Sargam Kapoor ◽  
Karen Ireland ◽  
Janine Keenan ◽  
...  

Abstract Background: Sickle cell disease (SCD) is characterized by abnormal cellular adhesion to the endothelium, contributing to progressive vasculopathy and vaso-occlusion. The progression of the underlying pathophysiology in SCD with age is not well understood. We evaluated red blood cell (RBC) adhesion at clinical baseline to laminin (LN) in children and adults with HbSS, using the SCD Biochip.1 The SCD Biochip is a microfluidic device that recapitulates physiologic flow and allows quantitation of RBC adhesion to biological surfaces.1 Methods: This prospective cross-sectional study was conducted at The Children's Hospital at Montefiore in the Bronx, NY and University Hospitals Adult Sickle Cell Clinic in Cleveland, OH between 2014 and 2017. Blood samples were obtained from 29 children 8 to 18 years of age (33 samples, 28 HbSS and 1 HbSS HPFH (hereditary persistence of fetal hemoglobin), 13 males and 16 females), from 61 young adult patients 18 to 40 years of age (117 samples, 53 HbSS and 8 HbSS HPFH, 32 males and 29 females), and from 20 older adult patients >40 years of age (38 samples, 16 HbSS and 4 HbSS HPFH, 9 males and 11 females). All blood samples were obtained at clinical baseline. Of the children, young adult, and older adult populations, 45%, 46%, and 40% were on hydroxyurea treatment, respectively. Adhesion experiments were performed using surplus whole blood passed at physiological flow through LN-immobilized microchannels, and quantified after a wash step via microscope based on published protocols.1 Median values were used for multiple samples from a single individual. Results: Adults had higher, more heterogeneous RBC adhesion (440 ± 654, N=81) than did children (90 ± 193, N=29, not shown, p<0.001). Young adults tended to have higher adhesion than older adults (n.s.), as well as children (P<0.001, Figure 1). Young adults also had higher pain levels (relative to children, P=0.002) and higher reticulocyte counts (relative to older adults, Table 1, p=0.011), despite a higher total Hgb (P=0.012). As expected, children had a higher hemoglobin F level than young adults (Table 1, 11.1 ± 6.74 vs 4.85 ± 6.90, p=0.011). Conclusions: Our data demonstrates that adult patients with SCD have higher and more variable adhesion compared to pediatric patients with SCD, and this may be especially true in young adults. Older adults tended to have lower adhesion (perhaps due to compensatory genetic mutations that allowed them to survive before optimal pediatric care), but this was not statistically significant. Recall, as recently as the 1970s half of all Americans with SCD died before the age of 15 years of age. However, modern children with SCD are being treated aggressively with transfusions or hydroxyurea, and their low overall RBC adhesion reflects either these interventions or an innate low RBC adhesion during childhood. Increased adhesion in RBCs from young adults with SCD is congruent with increased mortality in the transition population2, and strongly suggests that modern treatments, as currently prescribed and taken, are insufficient to completely reverse the abnormal red cell physiology seen in young adults. Young adults have an increased RBC adhesion, possibly reflective of the natural history of SCD, and may benefit the most from anti-adhesive therapies and intensive interventions. Lower adhesion in children with SCD may also reflect an overall improved response to therapeutic interventions in children. References: Alapan Y, Kim C, Adhikari A, Gray KE, Gurkan-Cavusoglu E, Little JA, Gurkan. Transl Res. 2016 Jul;173:74-91.e8. doi: 10.1016/j.trsl.2016.03.008. Epub 2016 Mar 19. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Blood. 2010 Apr 29;115(17):3447-52. Disclosures Little: NHLBI: Research Funding; Doris Duke Charitable Foundations: Research Funding; PCORI: Research Funding; Hemex: Patents & Royalties: Patent, no honoraria.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4851-4851
Author(s):  
Madeleine M Verhovsek ◽  
Alannah Delahunty-Pike ◽  
Uma H. Athale

Abstract Transition from pediatric to adult care is a well-recognized challenge for adolescents and young adults (AYA) with sickle cell disease (SCD) and thalassemia. Transition of care for AYAs is a multi-layered process, involving the patient, their family, and healthcare providers, with an end goal of ensuring that transition is as smooth as possible for all parties involved. In 2013, McMaster University launched a comprehensive care clinic for patients with SCD and thalassemia where a pediatric hematologist and an adult hematologist work side-by-side, along with a shared team of allied health care providers. One goal of this clinic is to facilitate fluid transition, by maintaining continuity in the patient’s medical care and providing a familiar environment for AYA patients. The aim of this study was to assess baseline level of understanding about transition from pediatric patients and their parents, expectations for transition, and recommendations for a smooth transition. In addition, opinions and experiences from young adult patients who had experienced transition of care under a variety of models were collected in order to identify key elements of how to optimally facilitate transition of care. After an informed consent process, 17 participants were interviewed regarding their, or their child’s, transition of care. Interviews were conducted with 5 pediatric patients, 5 parents, and 7 young adults. One-on-one semi-structured interviews were conducted with questions ranging from types of medical visits, knowledge of transition, experiences with transition, and recommendations. Saturation was reached and data was analyzed using an inductive-iterative approach. Eight SCD patients and 4 thalassemia major patients participated in the study. Themes that emerged included: apprehension from pediatric patients about leaving a supportive care environment; desire for a patient orientation with both their pediatric and adult specialists prior to transition; desire for a peer support group from pediatric patients, young adult patients and families; and need for a well established transition education piece for patients and families. Young adult patient experiences were diverse, as most had experienced SCD or thalassemia care at different hospitals. Patients who had transitioned in the McMaster clinic were pleased with the opportunity to participate in clinic visits attended jointly by their pediatric and adult hematologists prior to transition of care. Patients were appreciative of the continuous involvement of other clinic staff. The baseline responses obtained from this study can guide policies in a combined pediatric-adult model Hemoglobinopathy Clinic. Completing transition of care “under one roof” has potential to provide a uniquely supportive environment for AYA patients. An overlap in clinic staff for pediatric and adult patients can facilitate a strong patient rapport with a consistent set of healthcare providers, and can help to ensure consistency of care and collaboration between providers as patients transition through the AYA stages of life. Steps can be put in place to ensure that transition is as undisruptive as possible and to eliminate patients feeling uncertain about their care process. Disclosures No relevant conflicts of interest to declare.


2020 ◽  
Vol 19 (1) ◽  
pp. 47-52
Author(s):  
M. N. Korsantya ◽  
Y. E. Romankova ◽  
N. V. Myakova ◽  
A. V. Pshonkin

In many international studies, brentuximab vedotin (BV) has been shown to be highly effective in adult patients with primary refractory forms or recurrent Hodgkin’s lymphoma (HL). The group of children and adolescents received BV is not sufficient yet to assess the effectiveness and toxicity as in adults. In multicenter randomized trials BV was shown to be highly effective in adult patients. Aims: to evaluate the effectiveness and toxicity of anti-relapse therapy with BV followed by hematopoietic stem cell transplantation in children, adolescents and young adults with primary refractory forms of Hodgkin's Lymphoma (HL) and in patients with relapses of the disease. This study was approved by the Independent Ethical Committee and the Academic Council of Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation. In the 2012–2019 period 54 patients with primary refractory course and relapses of LH (Hodgkin's Lymphoma) were enrolled, among them 24 (44.4%) boys and 30 (55.6%) girls aged 4 to 25 years at the time of diagnosis of HL (average age-13.84.4 years). Therapy included BV as a part of block BB (brentuximab vedotin, ribomustin, dexamethasone) (n = 44) and BV monotherapy (n = 12). Complete response was achieved for 44 (81.4%) patients (pts) received BV (as a part of block BB - 37 pts and as monotherapy – 7 pts). Seven (12.9%) among 54 patients were transferred to therapy with PDL1 inhibitors (nivolumab, pembrolizumab) due to progression/refractoriness. Three (5.7%) patients were lost from observation. In our study, toxicity was observed in 7.4% of patients (n = 4) received brentuximab as a part of block BB: grade 4 hematological toxicity (n = 3) and infectious complications in the form of mucositis (n = 1). There was no evidence of any toxicity among pts received BV as monotherapy. BV in children, adolescents and young adults with primary refractory course and relapses of LH had shown high efficiency, which was not accompanied by significant toxicity.


2019 ◽  
Vol 3 (4) ◽  
Author(s):  
Teresa de Rojas ◽  
Anouk Neven ◽  
Mitsumi Terada ◽  
Miriam García-Abós ◽  
Lucas Moreno ◽  
...  

Abstract Background The 18-year-old age limit for inclusion in clinical trials constitutes a hurdle for adolescents and young adults (AYAs) with cancer. We analyzed the impact of this age barrier on the access of AYAs to cancer trials and novel therapies. Methods ClinicalTrials.gov was searched to identify all the trials including patients with 10 malignancies relevant for AYAs (January 2007 to July 2018). The trials were categorized as pediatric (patients &lt;18 y), adult (≥18 y), and transitional (including adult and pediatric patients). Transitional trials with a lower limit between 12 and 18 years and an upper limit younger than 40 years were considered AYA-specific. Results Of 2764 identified trials, 2176 were included: 79% adult, 19% transitional, 2% pediatric. Five trials were AYA-specific. The proportion of academic trials was higher for transitional (69%; 288 of 421) than for adult trials (48%; 832 of 1718) (P &lt; .0001). The total number of new trials increased over the years (156 in 2007; 228 in 2017); however, the number of transitional trials remained stable. The availability of trials increased with age, with a major increase at age 18 years: at age 17 years, 20% (442 of 2176) of trials were potentially accessible vs 95% (2075 of 2176) at 18 years. For trials investigating targeted therapies, this increase was 460% (197 trials available at age 17 years; 901 at 18 years) and for immunotherapies, 1200% (55 at age 17 years; 658 at 18 years). Conclusions AYAs have limited access to cancer trials and innovative therapies, with no improvement over the last decade. The 18-years-old age limit continues to be a major hurdle. Our findings are consistent with the internationally supported idea that age inclusion criteria in oncological trials should be changed.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2087-2087 ◽  
Author(s):  
Shanmuganathan Chandrakasan ◽  
Rebecca Marsh ◽  
Michael Grimley ◽  
Jack Bleesing ◽  
Michael Jordan ◽  
...  

Abstract Hemophagocytic lymphohistiocytosis (HLH) is a potentially life-threatening disorder of immune deregulation characterized by overwhelming immune activation and inflammation. Primary HLH was once thought to affect predominantly infants and young children. However, with increasing awareness, HLH is being diagnosed in adolescents and young adults. Currently, allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy available for primary hemophagocytic lymphohistiocytosis (primary HLH). There is limited data on HCT outcome for adolescents and young adults with HLH. We reviewed the allogeneic HCT outcomes of 19 adolescents and young adults with HLH (12 males and 7 females) who underwent HCT from January 2000 to June 2013 at our center. The median age at transplantation was 18.2 years (range: 15.2 -27.2). The Majority (15/19) underwent reduced-intensity conditioning (RIC) regimen consisting of alemtuzumab, fludarabine, and melphalan. Thirteen patients received transplants from HLA- matched donors (10 MUD and 3 MSD). Bone marrow was the source of stem cells in 15 patients. The HCT outcome of this group was compared to outcome of children with HLH less than 15 years of age. Median follow up of adolescent and young adult patients following HCT is 280 days (range 9-1643 days). Mixed donor chimerism was noted in 20% (3/15) of patients who received RIC. Acute GVHD grade II-IV was noted in four patients. Overall survival for adolescent and young adult patients was 42.1% (8/19). In patients who received RIC, Kaplan Meier analysis revealed a long term estimated survival of 57%, compared to 75% for children less than 15 years of age (p=0.03). Cox proportional hazard modeling revealed a reduced risk of mortality in young patients undergoing RIC HCT compared to adolescent and young adult patients (HR 0.379 [0.154-0.933], p=0.035), controlling for donor match and source. Deaths in adolescent and young adult patients occurred from days +9 to +568 following HCT. The cause of death varied from fulminant bacterial sepsis (n=4), acute refractory GVHD (n=2), disseminated aspergillus and fungal sepsis (n=2), viral infection (n=2), and refractory chronic GVHD (n=1). In conclusion, adolescents and young adults with HLH who undergo allogeneic HCT are at increased risk of mortality compared to younger patients. Further studies are needed to identify risk factors and potential interventions to improve HCT outcome for adolescents and young adults with HLH. Disclosures: No relevant conflicts of interest to declare.


2014 ◽  
Vol 55 (8) ◽  
pp. 1849-1853 ◽  
Author(s):  
Diane Coso ◽  
Sylvain Garciaz ◽  
Benjamin Esterni ◽  
Florence Broussais-Guillaumot ◽  
Vadim Ivanov ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document